JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Essman, S. C.
Right arrow Articles by Miller, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Essman, S. C.
Right arrow Articles by Miller, W. H.
Journal of Nuclear Medicine Vol. 46 No. 12 2076-2082
© 2005 by Society of Nuclear Medicine


Basic Science Investigations

Intraorgan Biodistribution and Dosimetry of 153Sm-Ethylenediaminetetramethylene Phosphonate in Juvenile Rabbit Tibia: Implications for Targeted Radiotherapy of Osteosarcoma

Stephanie C. Essman, DVM1, Michael R. Lewis, PhD1,2,3 and William H. Miller, PhD3

1 Department of Veterinary Medicine and Surgery, University of Missouri-Columbia, Columbia, Missouri
2 Department of Radiology, University of Missouri-Columbia, Columbia, Missouri
3 Nuclear Science and Engineering Institute, University of Missouri-Columbia, Columbia, Missouri

Targeted radiotherapy using 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) is currently under investigation for treatment of primary osteosarcoma. Human osteosarcoma most frequently occurs in skeletally immature individuals, and previous studies in a juvenile rabbit model demonstrated that clinically significant damage to developing physeal cartilage might occur as a result of systemic 153Sm-EDTMP therapy. The aim of this study was to determine the distribution of 153Sm-EDTMP within the tibias of juvenile rabbits and estimate the radiation-absorbed doses delivered to the physeal cartilage. Methods: Eight-week-old New Zealand White rabbits were injected intravenously with 7.57 kBq (280 µCi) of 153Sm-EDTMP. At 21 h after injection, the biodistribution of 153Sm in the epiphysis, metaphysis, diaphysis, and red marrow of the tibia was obtained. Two-dimensional digital autoradiography was performed on 2-mm sections of tibias for qualitative comparison with the biodistribution data. Self-tissue and cross-tissue absorbed doses were calculated using absorbed fractions generated by the Monte Carlo particle transport code MCNP-4C. Results: The highest uptakes (percentage injected dose per gram [%ID/g] of tissue) of 153Sm, 1.99–2.56 %ID/g, were found in the proximal and distal metaphyses, 70%–73% of which localized within 3 mm of the physeal cartilage. The second highest tissues of uptake were the proximal and distal epiphyses, at 0.33–0.62 %ID/g. Digital autoradiography imaging confirmed that the majority of 153Sm deposited in the tibia localized to these tissues. Radiation-absorbed doses to the proximal and distal metaphyses were 183 and 130 mGy/MBq, respectively, and those to the proximal and distal epiphyses were 141 and 43.4 mGy/MBq, respectively. These tissues represented the only source compartments contributing to the physeal cartilage doses of 50.0 mGy/MBq for the proximal physis and 39.2 mGy/MBq for the distal physis. Conclusion: The 153Sm absorbed doses to the physeal cartilage were consistent with values that can cause dose-limiting damage to rapidly proliferating and differentiating chondrocytes. The pronounced uptake in the juvenile epiphysis indicates that the proliferating zone of the physis can be irradiated from multiple areas, which could increase the expression and degree of radiation damage. Further investigation of the effects of 153Sm-EDTMP on immature physeal cartilage is warranted to develop optimized treatment regimens.

Key Words: 153Sm-ethylenediaminetetramethylene phosphonate • osteosarcoma • physeal cartilage • absorbed dose


Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 7a-8a. [Full Text]  



This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Du, J. Honeychurch, M. Glennie, P. Johnson, and T. Illidge
Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma
Cancer Res., February 1, 2007; 67(3): 1335 - 1343.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.